Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women
Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women
复制标题
DOI：
10.1002/cncr.10791
复制
发表时间：
2002-09-01
期刊：
影响因子：
6.2
通讯作者：
Samet, J
中科院分区：
文献类型：
--
作者：
Li, R;Gilliland, FD;Samet, J
背景。激素替代疗法（HRT）可以缓解更年期症状并预防骨质疏松症，但有人担心长期使用可能会对乳腺癌风险产生不利影响。流行病学研究报告了关于 HRT 与绝经后乳腺癌风险之间关系的不一致的发现，并且关于少数族裔女性中 HRT 相关风险的信息很少。方法。为了调查 HRT 对西班牙裔女性乳腺癌风险的影响，我们检查了新墨西哥州女性健康研究 (NMWHS) 的数据，这是一项全州范围的病例对照研究，包括 366 名患有乳腺癌的绝经后女性和 403 名对照者。使用条件逻辑回归来估计比值比 (OR) 和 95% 置信区间 (95% CI)。 结果。在调整社会人口统计学、医疗和生殖因素后，我们发现长期使用雌激素替代疗法相关的风险增加（ERT；与使用短于 17 个月的 ERT 相比，使用超过 140 个月的 ERT 的 OR 为 2.57，95%CI，1.25-5.28）。此外，ERT 使用持续时间呈正趋势（P < 0.01）。西班牙裔绝经后女性似乎比非西班牙裔白人女性面临更高的风险（西班牙裔使用 ERT 超过 140 个月的 OR 为 5.53，95% CI，1.47-20.87；与 ERT 使用时间短于 17 个月相比，非西班牙裔的 OR 为 2.65，95% CI，0.95-7.34）。相比之下，无论是西班牙裔还是非西班牙裔女性，雌激素-孕激素联合使用均未观察到显着关联。结论。这项研究的结果表明，长期使用 ERT 会显着增加绝经后妇女患乳腺癌的风险。西班牙裔女性的风险明显高于非西班牙裔白人女性，尽管这些风险在统计上并不显着。
BACKGROUND. Hormone replacement therapy (HRT) alleviates menopausal symptoms and prevents osteoporosis, but there is concern that long-term use may have an adverse impact on breast carcinoma risk. Epidemiologic studies report inconsistent findings regarding the relationship between HRT and postmenopausal breast carcinoma risk and there is little information on the HRT-associated risk among minority women.METHODS. To investigate the effects of HRT on breast carcinoma risk among Hispanic women, we examined data from the New Mexico Women's Health Study (NMWHS), a statewide case-control study comprising 366 postmenopausal women with breast carcinoma and 403 controls. Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals (95% CI).RESULTS. After adjustment for sociodemographic, medical, and reproductive factors, we found an increased risk associated with long-term users of estrogen replacement therapy (ERT; OR for ERT use longer than 140 months was 2.57, 95%CI, 1.25-5.28, compared with ERT use shorter than 17 months). In addition, there was a positive trend with the duration of ERT use (P < 0.01). Hispanic postmenopausal women appeared to be at a significantly greater risk than non-Hispanic white women (OR for ERT use longer than 140 months in Hispanics was 5.53, 95% CI, 1.47-20.87; OR in non-Hispanics was 2.65, 95% CI, 0.95-7.34, compared with ERT use shorter than 17 months). In contrast, no significant association was observed for combined estrogen-progesterone use in either Hispanic or non-Hispanic women.CONCLUSIONS. The results of this study indicated that postmenopausal women had significantly increased breast carcinoma risk for long-term ERT use. The risks among Hispanic women were substantially higher than among non-Hispanic white women although they were not statistically significant.